









Markets
/
Stocks
/
nasdaq-cbus
/

Cibus Inc

CBUS

2.080USD

-0.160-7.14%

Close 02/06, 16:00（ET）Quotes delayed by 15 min

109.34MMarket Cap

LossP/E TTM



Cibus Inc

2.080

-0.160-7.14%

Overview Financials Analysis Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Financials

Analysis

Company

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Cibus Inc

Currency: USD Updated: 2026-02-06

Key Insights

Cibus Inc's fundamentals are relatively stable, with an industry-leading ESG disclosure.and its growth potential is good.Its valuation is considered fairly valued, ranking 127 out of 205 in the Healthcare Equipment & Supplies industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 14.30.In the medium term, the stock price is expected to trend up.Despite a good stock market performance over the past month, the company shows weak fundamentals and technicals, which don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Cibus Inc's Score

Industry at a Glance

Industry Ranking

127 / 205

Overall Ranking

356 / 4521

Industry

Healthcare Equipment & Supplies

Support & Resistance

Relevant data have not been disclosed by the company yet.

Score Analysis

Current score

Previous score

Media Coverage

Last 24 hours

Coverage Level

Very Low

Very High

Neutral

Cibus Inc Highlights

StrengthsRisks

Cibus, Inc. is an agricultural technology company that uses gene-editing technologies to develop plant traits in seeds. Its business is the development of plant traits for some of the agricultural food crops that help address specific productivity, profitability, sustainability, or yield challenges in farming. Its core technology propriety gene editing platform is called the Rapid Trait Development System (RTDS). It is the underlying technology in the Company's Trait Machine process, an end-to-end semi-automated high-throughput gene editing system that directly edits seed companies' elite germplasm. It has a pipeline of five productivity traits. It has developed the productivity trait Pod Shatter Reduction (PSR) in Canola and Winter Oilseed Rape (WOSR) strengthens the sheath around the canola seeds. Its advanced productivity traits, Sclerotinia resistance and HT2 in Canola and WOSR, continue to progress and offer white mold disease resistance and broadleaf weed herbicide tolerance.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 2614.65% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 4.26M.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 4.26M.

Fairly Valued

The company’s latest PE is -0.77, at a medium 3-year percentile range.

Held by The Vanguard

Star Investor The Vanguard holds 1.24M shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.12.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

14.300

Target Price

+538.39%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Financial Health

Currency: USD Updated: 2026-02-06

The current financial score of Cibus Inc is 4.94, ranking 203 out of 205 in the Healthcare Equipment & Supplies industry. Its financial status is weak, and its operating efficiency is low. Its latest quarterly revenue reached 615.00K, representing a year-over-year decrease of 63.11%, while its net profit experienced a year-over-year decrease of 86.92%.

Score

Industry at a Glance

Previous score

4.94

Change



Financials

4.31

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

Relevant data have not been disclosed by the company yet.



Quality of Earnings

6.92

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

Relevant data have not been disclosed by the company yet.



Operational Efficiency

2.83

Key Metrics

Cash flow from operating activities

Income after tax

Relevant data have not been disclosed by the company yet.



Growth Potential

3.58

Key Metrics

Cash flow from operating activities

Total revenue

Relevant data have not been disclosed by the company yet.



Shareholder Returns

7.07

Key Metrics

Free cash flow

Relevant data have not been disclosed by the company yet.

Cibus Inc's Company Valuation

Currency: USD Updated: 2026-02-06

The current valuation score of Cibus Inc is 8.68, ranking 13 out of 205 in the Healthcare Equipment & Supplies industry. Its current P/E ratio is -0.77, which is -89.72% below the recent high of -0.08 and -196.05% above the recent low of -2.27.

Score

Industry at a Glance

Previous score

8.68

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 127/205

Relevant data have not been disclosed by the company yet.

Earnings Forecast

Currency: USD Updated: 2026-02-06

The current earnings forecast score of Cibus Inc is 7.33, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The average price target is 15.50, with a high of 25.00 and a low of 1.60.

Score

Industry at a Glance

Previous score

7.33

Change

Support & Resistance

Relevant data have not been disclosed by the company yet.

Analyst Rating

Based on 3 analysts

Buy

Current Rating

14.300

Target Price

+538.39%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

Total

Median

Average

Company name

Ratings

Analysts

Cibus Inc

CBUS

Intuitive Surgical Inc

ISRG

Boston Scientific Corp

BSX

Edwards Lifesciences Corp

Veeva Systems Inc

VEEV

Thermo Fisher Scientific Inc

TMO

...

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

Relevant data have not been disclosed by the company yet.

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2026-02-06

The current price momentum score of Cibus Inc is 4.35, ranking 190 out of 205 in the Healthcare Equipment & Supplies industry. Currently, the stock price is trading between the resistance level at 2.49 and the support level at 1.57, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

4.58

Change

-0.23

Support & Resistance

Relevant data have not been disclosed by the company yet.

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

0.071

Buy

RSI(14)

56.040

Neutral

STOCH(KDJ)(9,3,3)

73.768

Sell

ATR(14)

0.230

Low Volatility

CCI(14)

84.053

Neutral

Williams %R

32.609

Buy

TRIX(12,20)

0.610

Sell

StochRSI(14)

0.000

Sell

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.196

Sell

MA10

2.013

Buy

MA20

1.904

Buy

MA50

1.770

Buy

MA100

1.590

Buy

MA200

1.687

Buy

Institutional Confidence

Currency: USD Updated: 2026-02-06

The current institutional shareholding score of Cibus Inc is 3.00, ranking 134 out of 205 in the Healthcare Equipment & Supplies industry. The latest institutional shareholding proportion is 29.24%, representing a quarter-over-quarter decrease of 0.41%. The largest institutional shareholder is The Vanguard, holding a total of 1.24M shares, representing 1.83% of shares outstanding, with 33.18% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

Relevant data have not been disclosed by the company yet.

Shareholder Activity

Name

Shares Held

Chg %

Riggs (Rory B)

14.63M

+396.82%

Fidelity Management & Research Company LLC

7.34M

+2.43%

JPL Investments SA

1.67M

-0.73%

The Vanguard Group, Inc.

Star Investors

962.37K

+12.41%

Vantage Consulting Group, Inc.

1.14M

Beetham (Peter Ronald)

382.44K

Gocal (Gregory Francis William)

374.84K

+19.06%

BlackRock Institutional Trust Company, N.A.

282.15K

-38.15%

Certior Financial Group, LLC

184.79K

+6.47%

Risk Assessment

Currency: USD Updated: 2026-02-06

The U.S. Dollar Index is currently in a neutral state, which has a neutral effect on the Healthcare Equipment & Supplies domestic-focused industry. The Dollar Index (DXY) measures the value of the U.S. dollar against a basket of major currencies, including the euro, yen, pound sterling, Canadian dollar, Swedish krona, and Swiss franc. The current risk assessment score of Cibus Inc is 1.90, ranking 171 out of 205 in the Healthcare Equipment & Supplies industry. The company's beta value is 1.76. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets. with an industry-leading ESG disclosure.